Literature DB >> 15136305

The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Mahboob Rahman1, Clinton D Brown, Josef Coresh, Barry R Davis, John H Eckfeldt, Nelson Kopyt, Andrew S Levey, Chuke Nwachuku, Sara Pressel, Efrain Reisin, Candace Walworth.   

Abstract

BACKGROUND: The prevalence of reduced glomerular filtration rate (GFR) in older hypertensive patients and the relationship between level of GFR and cardiovascular disease (CVD) and its risk factors are not well known.
METHODS: We evaluated baseline renal function in 40 514 hypertensive patients 55 years or older who were enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). We used the simplified Modification of Diet in Renal Disease study equation to estimate GFR and examined the prevalence of CVD in patients with different levels of GFR.
RESULTS: Fifty-seven percent of patients had mild (60-89 mL/min per 1.73 m(2)), 17.2% had moderate (30-59 mL/min per 1.73 m(2)), and 0.6% had severe (<or=29 mL/min per 1.73 m(2)) reductions in GFR. Compared with patients with normal or mildly reduced GFR, patients with moderate or severe reductions in GFR were more likely to have had a prior myocardial infarction or stroke (19.2% and 23.4% vs 28.7% and 26.9%, respectively), have ischemic changes on electrocardiography (ECG) (16.0% and 18.9% vs 24.6% and 34.1%, respectively), and have left ventricular hypertrophy on ECG (ECG-LVH) (3.9% and 4.2% vs 6.0% and 11.2%, respectively). A decrease in GFR of 10 mL/min per 1.73 m(2) was independently associated with a 6% higher risk for CVD and 14% higher risk for ECG-LVH. The increase in risk was marked at a GFR of approximately 60 to 70 mL/min per 1.73 m(2).
CONCLUSIONS: The prevalence of reduced GFR is high in older hypertensive patients. Patients with moderate or severe reduction in GFR are more likely to have a history of CVD and ECG-LVH. Even modest reductions in GFR are independently associated with a higher prevalence of CVD and ECG-LVH.

Entities:  

Mesh:

Year:  2004        PMID: 15136305     DOI: 10.1001/archinte.164.9.969

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  15 in total

Review 1.  The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?

Authors:  Mahboob Rahman; Ashraf El-Meanawy; Joseph Romanello
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

2.  Hypertension is an important risk determinant for chronic kidney disease: results from a cross-sectional, observational study from a rural population in South India.

Authors:  Y J Anupama; S N Hegde; G Uma; M Patil
Journal:  J Hum Hypertens       Date:  2016-11-24       Impact factor: 3.012

3.  A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study.

Authors:  Nisha Bansal; Martin Keane; Patrice Delafontaine; Daniel Dries; Elyse Foster; Crystal A Gadegbeku; Alan S Go; L Lee Hamm; John W Kusek; Akinlolu O Ojo; Mahboob Rahman; Kaixiang Tao; Jackson T Wright; Dawei Xie; Chi-yuan Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

4.  Determinants and prognostic significance of electrocardiographic left ventricular hypertrophy criteria in chronic kidney disease.

Authors:  Rajiv Agarwal; Robert P Light
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 8.237

5.  Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

Authors:  Mahboob Rahman; Charles E Ford; Jeffrey A Cutler; Barry R Davis; Linda B Piller; Paul K Whelton; Jackson T Wright; Joshua I Barzilay; Clinton D Brown; Pedro J Colon; Lawrence J Fine; Richard H Grimm; Alok K Gupta; Charles Baimbridge; L Julian Haywood; Mario A Henriquez; Ekambaram Ilamaythi; Suzanne Oparil; Richard Preston
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-05       Impact factor: 8.237

6.  Changes in survival among elderly patients initiating dialysis from 1990 to 1999.

Authors:  Sarbjit Vanita Jassal; Lilyanna Trpeski; Naisu Zhu; Stanley Fenton; Brenda Hemmelgarn
Journal:  CMAJ       Date:  2007-10-23       Impact factor: 8.262

Review 7.  Chronic kidney disease, heart failure and anemia.

Authors:  Sean A Virani; Amit Khosla; Adeera Levin
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

8.  Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.

Authors:  Vibha Bhatnagar; Daniel T O'Connor; Nicholas J Schork; Rany M Salem; Caroline M Nievergelt; Brinda K Rana; Douglas W Smith; George L Bakris; John P Middleton; Keith C Norris; Jackson T Wright; Deanna Cheek; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  J Hypertens       Date:  2007-10       Impact factor: 4.844

Review 9.  Chronic kidney disease: it's time to recognize its presence in our patients with hypertension.

Authors:  Jan Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

Review 10.  Dietary salt, blood pressure, and microalbuminuria.

Authors:  Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.